PMID- 26280805 OWN - NLM STAT- MEDLINE DCOM- 20160607 LR - 20181113 IS - 1872-6844 (Electronic) IS - 0920-1211 (Print) IS - 0920-1211 (Linking) VI - 116 DP - 2015 Oct TI - Intravenous anesthesia in treatment of nonconvulsive status epilepticus: Characteristics and outcomes. PG - 86-92 LID - S0920-1211(15)30027-9 [pii] LID - 10.1016/j.eplepsyres.2015.07.005 [doi] AB - OBJECTIVE: To determine factors associated with continuous anesthetic drug (IVAD) use in nonconvulsive status epilepticus (NCSE). METHODS: Retrospective cohort study of patients who met clinical and EEG criteria of NCSE from 2009 to 2014 at a tertiary academic medical center. Patients were categorized according to IVAD use. Outcome variables were response to treatment and in-hospital death. We used descriptive analyses for baseline characteristics and outcome variable differences among patients who did and did not receive IVAD. RESULTS: Forty-three patients had a total of 45 NCSE episodes. IVAD was used in 69% of the episodes. Patients treated with IVAD were younger (53.1 +/- 14.1 vs 64.1 +/- 13.3, p = 0.019). The episodes treated with IVAD occurred more frequently in patients with an acute neurologic pathology (58% vs 21%, p = 0.024) and those presenting in a coma (39% vs 7%, p = 0.030). NCSE resolved in 74% of the patients who received IVAD. Duration of NCSE did not differ significantly by treatment group. There were total 13 in-hospital deaths: ten in IVAD users vs three in the no-IVAD group (p > 0.05). Only one in-hospital death appeared to be a direct consequence of IVAD use. Mortality was more common among episodes that were not treated according to the published status epilepticus treatment guidelines compared to the episodes where guidelines were followed. CONCLUSION: Our findings showed that factors such as younger age, acute neurologic pathology and coma at presentation were associated with IVAD use in patients with NCSE. These factors should be controlled in the future outcome and effectiveness studies to determine the effect of IVAD use on outcome of NCSE. CI - Copyright (c) 2015 Elsevier B.V. All rights reserved. FAU - Uysal, Utku AU - Uysal U AD - Department of Neurology, Comprehensive Epilepsy Center, University of Kansas Medical Center, 3901 Rainbow Blvd Mailstop 1065, Kansas City, KS 66160, USA. Electronic address: uuysal@kumc.edu. FAU - Quigg, Mark AU - Quigg M AD - University of Virginia Department of Neurology, FE Dreifuss Comprehensive Epilepsy Program, PO Box 800394, Charlottesville, VA 22908, USA. Electronic address: quigg@virginia.edu. FAU - Bittel, Brennen AU - Bittel B AD - Department of Neurology, University of Kansas Medical Center, 3599 Rainbow Blvd. Mailstop 2012, Kansas City, KS 66160, USA. Electronic address: bbittel@kumc.edu. FAU - Hammond, Nancy AU - Hammond N AD - Department of Neurology, Comprehensive Epilepsy Center, University of Kansas Medical Center, 3901 Rainbow Blvd Mailstop 1065, Kansas City, KS 66160, USA. Electronic address: nhammond@kumc.edu. FAU - Shireman, Theresa I AU - Shireman TI AD - University of Kansas School of Medicine, Department of Preventive Medicine and Public Health, 3901 Rainbow Blvd. Mail Stop 1008, Kansas City, KS 66160, USA. Electronic address: tshireman@kumc.edu. LA - eng GR - UL1 RR033179/RR/NCRR NIH HHS/United States GR - UL1 TR000001/TR/NCATS NIH HHS/United States GR - UL1TR000001/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20150726 PL - Netherlands TA - Epilepsy Res JT - Epilepsy research JID - 8703089 RN - 0 (Anticonvulsants) SB - IM MH - Adult MH - Aged MH - Anesthesia, Intravenous/*methods MH - Anticonvulsants/therapeutic use MH - Cohort Studies MH - Electroencephalography MH - Epilepsy, Generalized/*drug therapy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Statistics, Nonparametric MH - Time Factors MH - *Treatment Outcome PMC - PMC4593398 MID - NIHMS723506 OTO - NOTNLM OT - Anesthetic drugs OT - Antiepileptic drugs OT - Benzodiazepines OT - Nonconvulsive status epilepticus OT - Refractory status epilepticus COIS- Disclosure of Conflict of Interest: The remaining authors have no conflicts of interest. EDAT- 2015/08/19 06:00 MHDA- 2016/06/09 06:00 PMCR- 2016/10/01 CRDT- 2015/08/18 06:00 PHST- 2015/05/16 00:00 [received] PHST- 2015/06/23 00:00 [revised] PHST- 2015/07/19 00:00 [accepted] PHST- 2015/08/18 06:00 [entrez] PHST- 2015/08/19 06:00 [pubmed] PHST- 2016/06/09 06:00 [medline] PHST- 2016/10/01 00:00 [pmc-release] AID - S0920-1211(15)30027-9 [pii] AID - 10.1016/j.eplepsyres.2015.07.005 [doi] PST - ppublish SO - Epilepsy Res. 2015 Oct;116:86-92. doi: 10.1016/j.eplepsyres.2015.07.005. Epub 2015 Jul 26.